阿尔多梅他尼布通过减轻线粒体功能障碍来减轻OGD/R诱导的心肌细胞损伤
Mian Xie1, Jiajia Hao1, Chen Chao1
1Department of General Practice, Shenzhen People's Hospital, (First Affiliated Hospital, Southern University of Science and Technology, Jinan University), Shenzhen 518020, China.
Tissue & cell
|January 6, 2026
概括
在恢复血液流动后,阿尔多梅他尼布可以保护心脏免受伤害. 这种新型药物通过激活AMPK和Nrf2通路来减少细胞死亡和炎症,在心肌缺血再输液损伤方面显示出治疗前景.
科学领域:
- 心血管研究研究心血管研究
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心肌缺血-反损伤 (MIRI) 导致严重的心脏损伤,治疗选择有限.
- 阿尔多梅他尼布是一种溶解体AMP激活蛋白激酶 (AMPK) 激活剂,具有潜力,但其在MIRI中的作用尚不清楚.
研究的目的:
- 调查阿尔多梅他尼布对MIRI的保护作用.
- 在MIRI中阐明aldometanib作用的潜在分子机制.
主要方法:
- 利用体外模型 (H9c2和AC16心肌细胞系) 来评估aldometanib的作用.
- 研究的机制包括氧化应激,炎症,铁亡,线粒体功能,线粒体和Nrf2激活.
- 在MIRI的动物模型中进行初步验证.
主要成果:
- 阿尔多梅他尼布促进了心肌细胞的增殖,减少了氧化应激和炎症.
- 证明阿尔多梅他尼布可以抑制铁亡并减轻心肌细胞损伤.
- 透露的阿尔多梅他尼布通过溶酶体AMPK激活增强了线粒细胞衰变,并通过Nrf2发挥抗氧化作用.
- 动物研究初步证实了减少组织损伤和功能障碍.
结论:
- 阿尔多梅他尼布对MIRI具有显著的心脏保护作用.
- 这项研究阐明了阿尔多梅他尼布的机制,涉及AMPK,线粒,Nrf2和抗氧化剂通路.
- 提供了aldometanib作为MIRI的潜在治疗候选者的证据.
更多相关视频
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
580
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.5K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
01:46Electron Transport Chain: Complex I and II
18.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.4K